Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone Extension Study in Bipolar I Disorder
NCT01575561Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jun 2012
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of lurasidone in bipolar I disorder, sponsored by Sumitomo Pharma America. Primary endpoint: Treatment-emergent Adverse Events at 12 weeks. Started Jun 2012; status: completed.
02
Drugs
lurasidone
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT01575561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01575561.